Sensorion announces the last patient’s last visit in SENS-111 Phase 2 clinical trial. pdfRead

Sensorion completes a capital increase of €18.1 million subscribed by leading biotech investors. pdfRead

Sensorion announces two presentations at AAO-HNSF 2019 in New Orleans. pdfread

Sensorion announces three presentations at IEB 2019 in Padua. pdfRead

Sensorion announces appointment of John Furey, former COO of Spark Therapeutics, as independent board member. pdfRead


20200910 pipeline


Patient center

Corporate presentation